Lower risk of severe checkpoint inhibitor toxicity in more advanced disease

BACKGROUND: Immune checkpoint inhibitor (ICI) can cause severe and sometimes fatal immune-related adverse events (irAEs). Since these irAEs mimick immunological disease, a female predominance has been speculated on. Nevertheless, no demographic or tumour-related factors associated with an increased...

Descripción completa

Detalles Bibliográficos
Autores principales: Verheijden, Rik J, May, Anne M, Blank, Christian U, van der Veldt, Astrid A M, Boers-Sonderen, Marye J, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, van den Eertwegh, Alfonsus J M, de Groot, Jan Willem B, van der Hoeven, Jacobus J M, Hospers, Geke A P, Piersma, Djura, van Rijn, Rozemarijn S, ten Tije, Albert J, Vreugdenhil, Gerard, van Zeijl, Michiel C T, Wouters, Michel W J M, Haanen, John B A G, Kapiteijn, Ellen, Suijkerbuijk, Karijn P M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670947/
https://www.ncbi.nlm.nih.gov/pubmed/33199288
http://dx.doi.org/10.1136/esmoopen-2020-000945

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670947/
https://www.ncbi.nlm.nih.gov/pubmed/33199288
http://dx.doi.org/10.1136/esmoopen-2020-000945

Ejemplares similares